Martin Šimkovič
Impact in
- Genetics top 1%
- Chronic Lymphocytic Leukemia Research
-
- Lymphoma Diagnosis and Treatment
Papers in
- Genetics 51
- Chronic Lymphocytic Leukemia Research 51
-
- Lymphoma Diagnosis and Treatment 39
- Co-authors
- Alessandra TedeschiCarol MorenoFatih DemırkanJan NovákJohn G. GribbenRichard GreilDevinder GillBertrand Anz
- Journals
- Blood (7 papers)Journal of Clinical Oncology (4 papers)Hematological Oncology (4 papers)Archives of Medical Science (3 papers)British Journal of Haematology (2 papers)
- Partner nations
- CzechiaUnited StatesAustralia
In The Last Decade
Martin Šimkovič
52 papers receiving 1.1k citations
Hit Papers
Peers
Comparison fields: 5 of 49
- Genetics 954
- Pathology and Forensic Medicine 797
- Hematology 282
- Immunology 340
- Gastroenterology 61
Countries citing papers authored by Martin Šimkovič
This map shows the geographic impact of Martin Šimkovič's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martin Šimkovič with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martin Šimkovič more than expected).
Fields of papers citing papers by Martin Šimkovič
This network shows the impact of papers produced by Martin Šimkovič. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martin Šimkovič. The network helps show where Martin Šimkovič may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Martin Šimkovič, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia Hit paper breakdown → | 2025 | 21 |
| 2 | 2024 | 5 | |
| 3 | 2024 | 6 | |
| 4 | 2022 | 1 | |
| 5 | 2022 | 11 | |
| 6 | 2022 | 79 | |
| 7 | 2022 | 65 | |
| 8 | 2021 | 15 | |
| 9 | 2021 | 1 | |
| 10 | 2021 | 9 | |
| 11 | ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia Hit paper breakdown → | 2020 | 252 |
| 12 | 2020 | 0 | |
| 13 | 2019 | 2 | |
| 14 | 2019 | 11 | |
| 15 | 2019 | 12 | |
| 16 | Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial Hit paper breakdown → | 2018 | 380 |
| 17 | 2017 | 5 | |
| 18 | 2016 | 7 | |
| 19 | 2016 | 6 | |
| 20 | 2012 | 18 |
About Martin Šimkovič
Martin Šimkovič is a scholar working on Genetics, Pathology and Forensic Medicine, Hematology, Immunology and Gastroenterology, having authored 57 papers that have together received 1.1k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (51 papers), Lymphoma Diagnosis and Treatment (39 papers), Immunodeficiency and Autoimmune Disorders (14 papers), Chronic Myeloid Leukemia Treatments (12 papers), Advanced Breast Cancer Therapies (7 papers), CNS Lymphoma Diagnosis and Treatment (4 papers), Viral-associated cancers and disorders (3 papers) and Monoclonal and Polyclonal Antibodies Research (3 papers). The work is most often cited by research in Genetics (954 citations), Pathology and Forensic Medicine (797 citations), Hematology (282 citations), Immunology (340 citations) and Gastroenterology (61 citations). Martin Šimkovič has collaborated with scholars based in Czechia, United States and Australia. Frequent co-authors include Alessandra Tedeschi, Carol Moreno, Fatih Demırkan, Jan Novák, John G. Gribben, Richard Greil, Devinder Gill, Bertrand Anz, Ian W. Flinn and Loree Larratt. Their work appears in journals such as Blood, Journal of Clinical Oncology, Hematological Oncology, Archives of Medical Science and British Journal of Haematology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.